Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8+ T cell cytolytic killing of melanoma cells

Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association

(2022) Chia-Chin Wu et al.   Nature Communications

Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma

(2022) Andrew Hsu et al.   CANCER BIOLOGY & THERAPY

Non-redundant activity of GSK-3α and GSK-3β in T cell-mediated tumour rejection

(2021) Lynette Steele et al.   iScience

Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab

(2021) Toshiki Iwai et al.   Scientific Reports

Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-receptor LAG-3 for Enhanced Anti-tumor Immunity

(2020) Christopher E. Rudd et al.   Cell Reports

The Landscape of Glycogen synthase kinase-3 beta (GSK-3b) Genomic Alterations in Cancer

(2020) Brittany A Borden et al.   MOLECULAR CANCER THERAPEUTICS

Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma

(2019) Xiaosheng Wu et al.   BLOOD

Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses

(2019) Ilyas Sahin et al.   CANCER BIOLOGY & THERAPY

9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer

(2019) Hiroo Kuroki et al.   Scientific Reports

9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma

(2018) Andrey V. Ugolkov et al.   ANTI-CANCER DRUGS

Anti–PD-1/anti–CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+T cell trafficking

(2018) David Taggart et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

(2017) Enfu Hui et al.   SCIENCE

Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models

(2017) Andrey Ugolkov et al.   Translational Oncology

GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents

(2017) Reem Karmali et al.   Oncotarget

Glycogen Synthase Kinase 3 Inactivation Compensates for the Lack of CD28 in the Priming of CD8+ Cytotoxic T-Cells: Implications for anti-PD-1 Immunotherapy

(2017) Alison Taylor et al.   Frontiers in Immunology

GSK-3 inhibition overcomes chemoresistance in human breast cancer

(2016) Andrey Ugolkov et al.   CANCER LETTERS

Systemic DC Activation Modulates the Tumor Microenvironment and Shapes the Long-Lived Tumor-Specific Memory Mediated by CD8+T Cells

(2016) Kanako Shimizu et al.   CANCER RESEARCH

Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8+ Cytolytic T Cell Responses

(2016) Alison Taylor et al.   IMMUNITY

Inhibition of GSK-3 Induces Differentiation and Impaired Glucose Metabolism in Renal Cancer

(2013) K. Pal et al.   MOLECULAR CANCER THERAPEUTICS

Glycogen synthase kinase 3β inhibitors induce apoptosis in ovarian cancer cells and inhibit in-vivo tumor growth

(2011) Tyvette S. Hilliard et al.   ANTI-CANCER DRUGS

CXCR3 in T cell function

(2011) Joanna R. Groom et al.   EXPERIMENTAL CELL RESEARCH

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS

(2011) Hagit Eldar-Finkelman et al.   Frontiers in Molecular Neuroscience

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Glycogen synthase kinase 3: more than a namesake

(2009) Geetha Vani Rayasam et al.   BRITISH JOURNAL OF PHARMACOLOGY